Skin & wound healing research peptides

Skin and wound research is the area where peptide pharmacology has the longest cosmetic and pre-clinical history. GHK-Cu underpins decades of dermal-regeneration work; LL-37 covers antimicrobial defence and re-epithelialisation; BPC-157 contributes angiogenic effects in vascular wound beds.

Wound healing is a tightly orchestrated biological process proceeding through haemostasis, inflammation, proliferation, and remodelling phases, each requiring precise cellular and molecular coordination. Disruption at any phase — chronic inflammation preventing transition to proliferation, inadequate angiogenesis limiting granulation tissue formation, or disordered matrix remodelling producing fibrotic scar — creates the clinical problems of chronic wounds, impaired healing in diabetic or elderly subjects, and excessive scarring. The peptides in the skin and wound category address these failure points through four distinct mechanisms: copper-mediated cuproenzyme activation and transcriptional remodelling (GHK-Cu), NO and VEGFR2-driven angiogenesis (BPC-157), actin-mediated keratinocyte migration and VEGF upregulation (thymosin beta-4), and direct antimicrobial action combined with EGFR transactivation and FPR2-mediated angiogenesis (LL-37). GHK-Cu (Gly-His-Lys complexed with Cu²⁺) has the longest pre-clinical and cosmetic history in this class. The copper(II) coordination complex acts as a vehicle for bioavailable copper delivery to two key cuproenzymes: lysyl oxidase, which cross-links collagen and elastin in the extracellular matrix, and superoxide dismutase (SOD), the principal intracellular antioxidant. Genome-wide microarray analysis in human dermal fibroblasts identified more than 4,000 genes regulated by more than 50% upon GHK-Cu exposure, including balanced upregulation of MMP-2/-9 alongside their inhibitors TIMP-1/-2, suggesting a coordinated remodelling programme rather than unchecked matrix synthesis (Pickart et al., ScientificWorldJournal, 2010). GHK-Cu additionally attenuates TGF-β1-driven Smad phosphorylation, reducing myofibroblast differentiation and pathological fibrosis — a mechanistically unusual profile that simultaneously promotes organised collagen deposition and restrains scar formation. In streptozotocin-diabetic rat wound models, topical GHK-Cu hydrogels accelerated full-thickness wound closure and increased hydroxyproline content, demonstrating pre-clinical relevance in the impaired-healing context. Thymosin beta-4 and its commercial fragment TB-500 contribute to skin wound healing primarily through cytoskeletal reorganisation, upregulation of laminin-5, and VEGF-mediated angiogenesis, with murine full-thickness excisional wound data showing approximately 40% faster closure compared with vehicle (Malinda et al., FASEB J, 2003). BPC-157 adds VEGFR2-Akt-eNOS pro-angiogenic activity and NO-system stabilisation to the wound bed, with topical and parenteral preparations demonstrating similar efficacy in rodent models. LL-37 occupies a dual role in skin wound research that distinguishes it from the others: it is both an essential antimicrobial effector and a direct driver of re-epithelialisation. As a cationic amphipathic alpha-helix, LL-37 disrupts anionic microbial membranes at concentrations in the low-micromolar range. Independently of this antimicrobial mechanism, it transactivates the epidermal growth factor receptor (EGFR) through ADAM-10/17-mediated HB-EGF shedding, driving keratinocyte proliferation and directed migration toward the wound margin. Its engagement of FPR2 (FPRL1) on endothelial cells also promotes tube formation and angiogenesis, as demonstrated in HUVEC cultures and chick chorioallantoic membrane assays (Koczulla et al., J Clin Invest, 2003). These properties make LL-37 expression at the wound edge a positive prognostic correlate of re-epithelialisation rate in human chronic leg ulcer biopsies (Heilborn et al., J Invest Dermatol, 2003). Standard assays in this category include full-thickness excisional wound models (murine dorsal skin punch biopsy), assessed by wound-area planimetry over sequential days, digital histomorphometry for epithelial gap closure and granulation tissue depth, CD31 immunostaining for microvessel density, and Masson's trichrome for collagen architecture. In vitro tools include scratch-wound migration assays in keratinocyte and fibroblast monolayers, TEER-based barrier-integrity measurement, and HUVEC tube-formation assays for angiogenic endpoint capture. No compound in this category holds MHRA marketing authorisation as a medicine. GHK-Cu is permitted as a cosmetic ingredient in the UK under the Cosmetic Products Regulation and is not on the WADA Prohibited List; LL-37 is similarly not WADA-listed. BPC-157 is WADA-prohibited under S0 and thymosin beta-4 under S2. Outstanding research questions include whether the anti-fibrotic profile of GHK-Cu translates to reduced hypertrophic scarring in controlled large-animal models, the optimal LL-37 concentration window that maximises wound-healing activity without triggering autoinflammatory side effects in susceptible skin, and whether combination regimens pairing BPC-157 or thymosin beta-4 with GHK-Cu provide additive matrix-remodelling outcomes.

Peptides in this category